- Home
- AVIR vs BGH Comparison
AVIR vs BGH Comparison
Compare AVIR & BGH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- BGH
- Stock Information
- Founded
- AVIR 2012
- BGH 2012
- Country
- AVIR United States
- BGH United States
- Employees
- AVIR N/A
- BGH N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- BGH Investment Managers
- Sector
- AVIR Health Care
- BGH Finance
- Exchange
- AVIR Nasdaq
- BGH Nasdaq
- Market Cap
- AVIR 290.4M
- BGH 331.7M
- IPO Year
- AVIR 2020
- BGH N/A
- Fundamental
- Price
- AVIR $3.14
- BGH $15.10
- Analyst Decision
- AVIR Hold
- BGH
- Analyst Count
- AVIR 1
- BGH 0
- Target Price
- AVIR $6.00
- BGH N/A
- AVG Volume (30 Days)
- AVIR 399.6K
- BGH 61.5K
- Earning Date
- AVIR 11-06-2025
- BGH 01-01-0001
- Dividend Yield
- AVIR N/A
- BGH 10.06%
- EPS Growth
- AVIR N/A
- BGH N/A
- EPS
- AVIR N/A
- BGH N/A
- Revenue
- AVIR N/A
- BGH N/A
- Revenue This Year
- AVIR N/A
- BGH N/A
- Revenue Next Year
- AVIR N/A
- BGH N/A
- P/E Ratio
- AVIR N/A
- BGH N/A
- Revenue Growth
- AVIR N/A
- BGH N/A
- 52 Week Low
- AVIR $2.46
- BGH $11.92
- 52 Week High
- AVIR $4.02
- BGH $14.50
- Technical
- Relative Strength Index (RSI)
- AVIR 52.91
- BGH 30.94
- Support Level
- AVIR $2.78
- BGH $14.79
- Resistance Level
- AVIR $2.94
- BGH $15.39
- Average True Range (ATR)
- AVIR 0.10
- BGH 0.26
- MACD
- AVIR 0.04
- BGH -0.10
- Stochastic Oscillator
- AVIR 90.79
- BGH 18.82
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About BGH Barings Global Short Duration High Yield Fund of Beneficial Interests
Barings Global Short Duration High Yield Fund is a diversified, closed-end management investment company. Its investment objective is to seek as high a level of current income as the Adviser determines is consistent with capital preservation.